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ABSTRACT
Objectives: To investigate the clinical and cost-
effectiveness of self-monitoring of coagulation status in
people receiving long-term vitamin K antagonist
therapy compared with standard clinic care.
Design: Systematic review of current evidence and
economic modelling.
Data sources: Major electronic databases were
searched up to May 2013. The economic model
parameters were derived from the clinical effectiveness
review, routine sources of cost data and advice from
clinical experts.
Study eligibility criteria: Randomised controlled
trials (RCTs) comparing self-monitoring versus
standard clinical care in people with different clinical
conditions. Self-monitoring included both self-
management (patients conducted the tests and
adjusted their treatment according to an algorithm) and
self-testing (patients conducted the tests, but received
treatment recommendations from a clinician). Various
point-of-care coagulometers were considered.
Results: 26 RCTs (8763 participants) were included.
Both self-management and self-testing were as safe as
standard care in terms of major bleeding events (RR
1.08, 95% CI 0.81 to 1.45, p=0.690, and RR 0.99,
95% CI 0.80 to 1.23, p=0.92, respectively). Self-
management was associated with fewer
thromboembolic events (RR 0.51, 95% CI 0.37 to
0.69, p≤0.001) and with a borderline significant
reduction in all-cause mortality (RR 0.68, 95% CI 0.46
to 1.01, p=0.06) than standard care. Self-testing
resulted in a modest increase in time in therapeutic
range compared with standard care (weighted mean
difference, WMD 4.4%, 95% CI 1.71 to 7.18, p=0.02).
Total health and social care costs over 10 years were
£7324 with standard care and £7326 with self-
monitoring (estimated quality adjusted life year, QALY
gain was 0.028). Self-monitoring was found to have
∼80% probability of being cost-effective compared
with standard care applying a ceiling willingness-to-pay
threshold of £20 000 per QALY gained. Within the base
case model, applying the pooled relative effect of
thromboembolic events, self-management alone was
highly cost-effective while self-testing was not.
Conclusions: Self-monitoring appears to be a safe
and cost-effective option.
Trial registration number: PROSPERO
CRD42013004944.
INTRODUCTION
Approximately 2% of the population are pre-
scribed long-term oral anticoagulant drugs
for atrial ﬁbrillation (AF),1–3 heart valve
disease,4–6 or other conditions with high risk
of thrombosis.7–9 Historically, treatment has
been with vitamin K antagonist therapy, with
dose-adjusted warfarin the most commonly
used drug. Recently, new oral anticoagulants
(NOACs) which do not require dose adjust-
ment, such as dabigatran etexilate, rivaroxa-
ban or apixaban, have been proposed as a
possible alternative to warfarin for the treat-
ment of AF.10 11 However, NOACs are unsuit-
able for people with artiﬁcial heart valves
Strengths and limitations of this study
▪ The study is the most up-to-date evidence syn-
thesis on this topic, with the largest number of
included randomised controlled trials.
▪ Clinical heterogeneity was observed among
included trials.
▪ The majority of the trials included participants
with mixed clinical indications for anticoagulation
therapy, which made it challenging to extrapolate
the results to specific clinical populations.
▪ The perspective of the economic modelling was
that of the National Health Service (NHS) and
personal social services, and did not capture any
wider benefit.
▪ Long-term outcomes data on self-management
from larger cohorts of people with different clin-
ical indications are needed.
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(AHF), people with liver or renal dysfunctions and those
who are taking concurrent medication, which may react
with this class of anticoagulants. For these people, war-
farin remains the long-term treatment of choice.
Furthermore, the lack of long-term evidence on these
novel anticoagulants compared with vitamin K antago-
nists induces some caution in their wide prescription.10
Typically, dose adjustment of vitamin K antagonist
therapy involves a blood test of clotting (international
normalised ratio, INR) with dose titration to maintain
this within a narrow therapeutic range (TTR).12 13
Underdosing of anticoagulation therapy increases the
risk of thromboembolism, while overdosing increases
the risk of bleeding events. Repeated and regular mea-
surements of INR, with dose adjustment when necessary,
are necessary to ensure safe and effective anticoagula-
tion therapy.14
Monitoring of anticoagulant treatment can be deliv-
ered in a number of different ways. These include full
service provision in specialist anticoagulation clinics, in
physician ofﬁces or general practices (either with
samples sent to a laboratory or with near-patient testing)
or self-monitoring8 in which patients carry out their own
tests at home using approved portable coagulometers,
which test a ﬁnger-prick blood sample. Self-monitoring
includes both self-management, in which patients
conduct tests and adjust their treatment according to an
algorithm; in self-testing, the patients conduct the tests,
but obtain treatment recommendations from a clinician
after sending them the results.
Several coagulometers are available, which have CE mar-
keting authorisation and Food and Drug Administration
(FDA) approval; these include the CoaguChek system (ver-
sions S and XS) (Roche Diagnostics, Basel, Switzerland),
the INRatio2 PT/INR monitor, (Alere Inc., San Diego,
California, USA) or the ProTime Microcoagulation system
(International Technidyne Corporation, ITC—Nexus Dx,
Edison, New Jersey, USA). Their precision and accuracy
compared with conventional laboratory-based clinical
testing have been reported in a number of studies in the
literature.15–17
The increased use of oral anticoagulants has intensi-
ﬁed pressure on healthcare resources.18 The use of
point-of-care coagulometers for self-monitoring may
avoid unnecessary visits to hospitals or clinics while per-
mitting more frequent INR monitoring and timely
adjustment of warfarin dosing to avoid adverse events.19
The evidence for the effectiveness of self-monitoring is
limited20 and previously published economic evaluations
have produced conﬂicting results.14 16 The aim of this
study is to assess the current evidence on the clinical
and cost-effectiveness of self-monitoring (self-testing and
self-management) in people receiving long-term vitamin
K antagonist therapy as an alternative to standard antic-
oagulation monitoring care. We focus mainly on the
current generation of point-of-care devices (eg,
CoaguChek XS), which utilised the most recent technol-
ogy to minimise measurement inaccuracies.
METHODS
Clinical effectiveness
The methods of the systematic review of clinical effective-
ness were prespeciﬁed and detailed in a research protocol
(http://guidance.nice.org.uk/DT/16/FinalProtocol/pdf/
English), and reported according to standard guide-
lines.21–24
Identification of studies
We identiﬁed a relevant systematic review published in
the Cochrane Library in 2010 by Garcia-Alamino et al,20
which included studies published up to 2007, and had
similar objectives to those of this study. Thus, the litera-
ture searches for this study were run in May 2013 for the
period ‘2007-to date’ to identify newly published reports.
All randomised controlled trials (RCTs) included in the
Garcia-Alamino et al’s20 review were obtained and
included for full-text assessment. Major electronic data-
bases such as MEDLINE, MEDLINE In-Process & Other
Non-Indexed Citations, EMBASE, Biosis, Science
Citation Index, and Cochrane Controlled Trials Register
(CENTRAL) were searched for relevant primary studies.
Evidence syntheses’ reports, conference abstracts (2011–
2013), and ongoing studies were sourced from relevant
databases. Reference lists of included studies were
perused for additional publications and experts in the
ﬁeld contacted for further information on relevant out-
comes and ongoing research in the ﬁeld. Searches were
restricted to publications in English. Full details of the
search strategies are presented in online supplementary
appendix 1.
Inclusion and exclusion criteria
We included RCTs comparing self-testing and/or self-
management of anticoagulation control using point-of-
care coagulometers with standard monitoring care,
which consisted of INR monitoring managed by health-
care professionals. We included studies of both adults
and children with heart valve disease (eg, AHV), AF or
other clinical indications who required long-term
vitamin K antagonist therapy. Main outcomes of interest
were: (1) major bleeding and thromboembolic events;
(2) all-cause mortality; (3) anticoagulation control mea-
sured as time and INR values in TTR, and other inter-
mediate outcomes (including frequency of testing,
frequency of visits to clinics, patient compliance with
testing).
Study selection and data extraction
Two authors independently screened the results of the lit-
erature searches, retrieved full-text copies of selected
studies and extracted relevant data (PS, MC). Information
on study design, characteristics of participants, settings,
characteristics of interventions and comparators, and
outcome measures was recorded for all included studies.
The Cochrane Risk of Bias tool was used to assess the risk
of bias in the included studies.22 Critical assessments of
selection, detection, attrition and reporting biases were
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performed initially by one author (PS) and cross-checked
by a second author (MC). Studies were not excluded
purely on the basis of their potential risk of bias. Any
uncertainty or disagreements during the study selection,
data extraction and risk of bias assessment was resolved by
discussion or arbitration by a third author (MB).
Data analysis
Where appropriate, pooled summary estimates were cal-
culated using Review Manager, software (Review
Manager V.5.2, Copenhagen: the Nordic Cochrane
Centre, The Cochrane Collaboration, 2012). In the pres-
ence of either clinical or statistical heterogeneity, a
random effects model was chosen as the preferred
method for pooling the effect sizes.21 Relative risk (RR)
together with 95% CIs were calculated for dichotomous
data (Mantel-Haenszel method), while weighted mean
difference (WMD) together with 95% CI were calculated
for continuous data (inverse-variance method). Where
SDs were not given, these were extrapolated, if possible,
using test statistics. Heterogeneity across studies was
explored by means of the χ2 statistic (with signiﬁcance
level at p<0.05) and the extent of inconsistency between
studies quantiﬁed by means of the I2 statistic. For trials
that had multiple arms contributing to different sub-
groups, the control group was subdivided into two
groups to avoid a unit of analysis error.
Cost-effectiveness analysis
A de novo Markov model was developed25 26 in TreeAge
Pro (TreeAge Software, Williamstown, Massachusetts,
2013) to assess the cost-effectiveness of self-monitoring
(self-testing and self-management). The model structure
was based on previous economic models of INR
self-monitoring published in the literature,14 27–34
including models assessing the cost-effectiveness of
NOAC drugs compared with warfarin in people with
AF.11 35 In addition, an unpublished economic model
was provided by Roche Diagnostics, the manufacturer of
the CoaguChek XS coagulometer ( J Craig, York Health
Economics Consortium, 2013). The model was built and
analysed in accordance with the National Institute for
Health and Care Excellence (NICE) reference case for
the evaluation of diagnostic tests and devices.36
Model framework and method of synthesis
The model was populated using data derived from the
systematic review of clinical effectiveness, other relevant
reviews to inform key parameters (eg, baseline risks),
and routine sources of cost data,37 38 and information
provided by clinical experts. The alternative monitoring
pathways were embedded in a Markov model simulating
the occurrence of adverse events over time for a hypo-
thetical cohort of people with AF or AHV (ﬁgure 1).
The model incorporated the pathways of care that indivi-
duals currently follow under standard practice in the
National Health Services (NHS)—standard monitoring
in primary care or in secondary care—as well as pro-
posed pathways for self-testing and self-management.
The cost-effectiveness of self-monitoring was assessed as
a whole assuming a 50:50 split between self-testing and
self-management. The model simulated transitions
between the discrete health states on a quarterly
(3-month) cycle. Appropriate costs and quality of life
weights were attached to modelled events and health
states, allowing cumulative health and social care costs
and quality adjusted life years (QALYs) to be modelled
over time. Full details of the modelling methods are pro-
vided in online supplementary appendix 2. The main
assumptions made for the base case analysis are sum-
marised in table 1. For the purpose of this study, it was
assumed that self-monitoring patients use the
CoaguChek XS system.
The results of the model are presented in terms of a
cost-utility analysis (ie, costs for and number of QALYs
generated by each monitoring strategy). Self-monitoring
Figure 1 Schematic of the
model structure.
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strategies were compared to standard care monitoring,
to estimate the incremental costs per QALY gained.
Both costs and beneﬁts (QALYs) were discounted at a
rate of 3.5% per annum, in line with the NICE reference
case.36 Cost are expressed in 2011/2012 Stirling. The
model was initially analysed over a 10-year period, but
the impact of adopting longer time horizons was
explored through sensitivity analyses. Further sensitivity
analyses focused on the standard care comparator
(primary care, secondary care), the proportional split
between the active interventions (self-testing, self-
management), the baseline risk of thromboembolic
events and the RRs associated with self-testing and self-
management. In addition, cost-minimisation scenarios
were considered (assuming an equal number of tests
with self-monitoring and standard care, and equivalence
in effects). Finally, the results of probabilistic sensitivity
analyses were used to express the parameter uncertainty
surrounding the base estimates of cost-effectiveness.
RESULTS
Clinical effectiveness
Of the 658 records retrieved, 26 RCTs published in 45
papers with a total of 8763 participants met the inclusion
criteria. Of the 26 included RCTs, 21 trials with a total of
8394 participants provided suitable data for statistical ana-
lyses relevant to the comparisons and outcomes of
interest. A ﬂow diagram outlining the selection process is
shown in online supplementary appendix 3.
The 26 included trials were conducted in Europe and
North America. Seventeen trials (17/26) compared self-
management with standard care,39–55 six assessed self-
testing,56–61 and one evaluated both self-testing and
self-management versus either trained or untrained
routine care (four arms).62 The remaining two trials
compared self-testing with self-management,63 64 one of
which focused exclusively on children.63 Two trials
enrolled exclusively participants with AF,55 59 six trials
limited inclusion to participants with AHV41 45 46 50 52 56
and 18 trials39 40 42–44 47–49 51 53 54 57 58 60–64 included
participants with mixed clinical indications. The major-
ity of the included trials (22/26) used the CoaguChek
system for INR monitoring. Two trials used either
INRatio or the CoaguChek S for INR measurement (but
did not present results according to the type of the
point-of-care device used),44 56 while the other two trials
used the ProTime system.53 60
Table 2 summarises the characteristics of the included
trials (full details are shown in online supplementary
appendix 4 table S1). The included trials varied in size
(16–2922 participants), the length of study duration
(3.5–57 months), the age of the included adult partici-
pants (16–91 years) and the type of standard care
(63.6% of the participants measured INR in secondary
care, 27.2% in primary care and 9.2% in mixed care
Table 1 Main assumptions made for the base case analysis and justification
Assumptions Justification
66.45% of standard care monitoring occurs in primary care
with practice nurses
Based on previous TAR (manufacturers submission for
TA256)70
60% of the cohort have atrial fibrillation, 40% have an
artificial heart valve
In line with the observed proportions of patients with these
conditions in self-monitoring trials68
Average age of the cohort is 65 years, and 55% are male In line with the observed mean age of included patients with
these conditions in self-monitoring trials68
50% of self-monitoring people self-test, 50% self-manage Self- assumption
The increase in the number of tests performed per year
with self-monitoring is 23
In line with the observed frequency of self-testing in
self-monitoring trials68
Relative treatment effects are estimated and applied
separately for self-testing and self-management
Derived from the observed event rates in cohorts of people
being managed under current standard models of care. Relative
risks of these events resulting from improved/reduced INR
control, conferred by self-monitoring, were derived from the
meta-analysis of RCTs of self-monitoring versus standard
practice. (see section on clinical effectiveness results)
15% of participants do not commence self-monitoring
following training
Based on the RCT literature43 and the expert advisory
committee consultation
10% of participants discontinue self-monitoring within a
year of commencing
Based on consideration of the views of the expert advisory
committee (∼5%) and a rate of 14% reported in the largest
UK-based trial.43
Self-monitoring device costs are annuitized over 5 years to
account for the potential for loss and accidental damage
It was assumed that the NHS would pay for devices and loan
them out to patients. As such they were annuitized over their
expected useful life, to provide an equivalent annual/quarterly
cost of use
75% of devices are reused by another patient when a
patient discontinues self-monitoring
In line with a previous UK-based economic evaluation71
TAR, technology assessment report; INR, international normalised ratio; RCT, randomised control trial; NHS, National Health Service.
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setting). In approximately 95% of the included partici-
pants, mean age was between 50 and 70 years. Nine
trials, which includes 75% of the total participants, had
study duration of more than or equal to 12
months.41 43 46 47 50–52 60 63 Three trials recruited partici-
pants who were new to anticoagulation therapy,46 48 51
two trials included participants receiving anticoagulants
for the past 1–2 months,53 61 12 trials recruited partici-
pants who had been on anticoagulants for at least
3 months before randomisation39 40 42 43 47 54 57–59 62–64
while the remaining trials did not provide this
information.
Only four trials were assessed to have adequate
sequence generation, concealed allocation and blinded
outcome assessment and therefore were judged at low
risk of bias.47 61 63 65 The remaining trials were judged
at ‘unclear’40–46 48–50 52 56 58 59 62 64 or ‘high’39 53–55 57 60
risk of bias (ﬁgure 2) (full details of the risk of bias
assessment are presented in online supplementary
appendix 4 table S2).
Major clinical outcomes
Major bleeding and major thromboembolic events were
reported in the majority of trials. Deﬁnitions varied
between the trials and not all trials used well-deﬁned cri-
teria. In general, major events (bleeding or thrombo-
embolic) were deﬁned as complications requiring
hospital admission or medical assessment. Fatal bleeding
and thromboembolic events were counted as deaths.
Table 3 shows the main ﬁndings of self-monitoring
(self-testing and self-management) compared with stand-
ard clinical monitoring.
Bleeding events
Twenty-one trials reported a total of 1472 bleeding
events (major and minor). No statistically signiﬁcant dif-
ferences were observed between either self-management
or self-testing, and standard monitoring care for major
bleeding events (RR 1.08, 95% CI 0.81 to 1.45, p=0.60
and RR 0.99, 95% CI 0.80 to 1.23, p=0.92, respectively)
(ﬁgure 3 and table 3). Self-testing was associated with a
Table 2 Summary of the characteristics of included trials
Characteristics Range Total number (%) Number of trials
Sample size, n 16–2922 8763 26
Self-monitoring, n 4553 (51.9)
PSM 14–579 2619 (57.5) 20*
PST 14–1465 1934 (42.5) 9*
Standard care, n 4199 (47.9)
AC clinic 17–1457 2669 (63.6) 15
GP/physician 26–576 1143 (27.2) 6
AC clinic or GP/physician 49 to103 387 (9.2) 5
Study duration, months 3.5–57†
<12 16–320 2186 (25) 17
≥12 28–2922 6577 (75) 9
Age, years 1–91
Mean age groups, years
Mean age ≤18 1–19 28 (<1) 1
Mean age >18 to <50 22–71 100 (∼1) 1
Mean age ≥50 to <70 16–91 8289 (94.6) 21
Mean age ≥70 65–91 85 (∼1) 1
Clinical indication, n
AF 85–202 287 (3) 2
AHV 58–1155 2434 (28) 6
Mixed indication 16–2922 6042 (69) 18
POC devices, n
CoaguChek 28–1155 5479 (62.5) 22
ProTime 140–2922 3062 (35.0) 2
INRatio2 – 0 0
CoaguChek+INRatio2 16–206 222 (2.5) 2
Outcomes, n
Thromboembolic events 49–2922 8394 (95.8) 21
Bleeding events 49–2922 8394 (95.8) 21
Mortality 49–2922 6537 (74.6) 13
Time in therapeutic range 28–2922 6245 (71.3) 18
INR values in range 49–1155 4472 (51) 12
*For conversion of study duration reported in week, 4 weeks was considered equivalent to 1 month.
†Three of the 26 trials reported both PSM and PST arms.62–64
PSM, patient self-management; PST, patient self-testing; AC, anticoagulation; GP, general practitioner; AF, atrial fibrillation; AHF, artificial
heart valves; POC, point-of-care; INR, international normalised ratio.
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small increased risk of minor bleeding events (RR 1.23,
95% CI 1.06 to 1.42, p=0.005) and all bleeding events
(RR 1.15, 95% CI 1.03 to 1.28, p=0.02) while self-
management was not (the RR for minor bleeding events
was 0.84, 95% CI 0.53 to 1.35, p=0.47 and for all bleed-
ing events 0.94, 95% CI 0.68 to 1.30, p=0.69).
No statistically signiﬁcant subgroup differences were
found for bleeding events by clinical indication for anti-
coagulant treatment (AHV only, AF only or mixed) or
by the setting for standard care (anticoagulant clinics
only, physician/GP ofﬁces only, or mixed practices).
Thromboembolic events
Twenty-one trials reported a total of 351 thrombo-
embolic events (major and minor) involving 8394 parti-
cipants.39–43 45–57 59–62 Self-monitoring was associated
with a statistically signiﬁcant reduction in the risk of
thromboembolic events (RR 0.58, 95% CI 0.40 to 0.84,
Figure 2 Summary of risk of
bias of all included studies.
Table 3 Meta-analyses results of major clinical outcomes and time in therapeutic range
Outcomes
Self-monitoring Standard care
RR (95% CI) p Value
Number
of trials
Number
of events
Total
number
Number
of events
Total
number
All bleeding 736 4278 736 4116 0.95 (0.74 to 1.21) 0.66 22*
Self-management 250 2403 310 2237 0.94 (0.68 to 1.30) 0.69 15
Self-testing 486 1875 426 1879 1.15 (1.03 to 1.28) 0.02 7
Major bleeding 247 4188 231 4014 1.02 (0.86 to 1.21) 0.82 21*
Self-management 96 2403 78 2237 1.08 (0.81 to 1.45) 0.60 15
Self-testing 151 1785 153 1777 0.99 (0.80 to 1.23) 0.92 6
Minor bleeding 489 2757 505 2668 0.94 (0.65 to 1.34) 0.73 13
Self-management 154 1081 232 1035 0.84 (0.53 to 1.35) 0.47 9
Self-testing 335 1676 273 1633 1.23 (1.06 to 1.42) 0.005 4
Thromboembolic events 149 4278 202 4116 0.58 (0.40 to 0.84) 0.004 22*
Self-management 54 2403 106 2237 0.51 (0.37 to 0.69) <0.0001 15
Self-testing 95 1875 96 1879 0.99 (0.75 to 1.31) 0.95 7
Mortality 197 3323 225 3214 0.83 (0.63 to 1.10) 0.20 13
Self-management 44 1674 68 1619 0.68 (0.46 to 1.01) 0.06 10
Self-testing 153 1649 157 1595 0.97 (0.78 to 1.19) 0.74 3
Time in therapeutic
range
NA 2598 NA 2521 WMD 2.82 (0.44 to 5.21) 0.02 11*
Self-management NA 870 NA 828 WMD 0.47 (−1.40 to 2.34) 0.62 6
Self-testing NA 1728 NA 1693 WMD 4.44 (1.71 to 7.18) 0.001 5
*For the subgroup meta-analysis according to type of anticoagulant therapy management—, a 4-armed trial, contributed to two studies: one
on self-testing and one on self-management.62
NA, not applicable; RR, relative risk; WMD, weighted mean difference.
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p=0.004) compared with standard care (ﬁgure 4). This
reduction was still apparent when the analysis was
restricted to major thromboembolic events (RR 0.52,
95% CI 0.34 to 0.80, p=0.003). The reduction in
thromboembolic events was observed only in studies of
patients carrying out self-management (RR 0.51, 95% CI
0.37 to 0.69, p<0.0001). There was no signiﬁcant risk
reduction among trials of self-testing (RR 0.99, 95% CI
0.75 to 1.31, p=0.56).
The observed reduction in thromboembolic events
was similar across clinical indications for anticoagulation:
AHV (6 studies, RR 0.56, 95% CI 0.38 to 0.82), AF
(2 studies, RR 0.33, 95% CI 0.01 to 8.09) and mixed
indications (13 studies, RR 0.57, 95% CI 0.30 to 1.09)
(test for subgroup differences: p=0.95). Similarly, there
were no signiﬁcant differences in observed reduction in
thromboembolic events among studies which conducted
standard care in anticoagulant clinics (10 studies, RR
0.65, 95% CI 0.30 to 1.42), physician/GP ofﬁces
(6 studies RR 0.45, 95% CI 0.31 to 1.38) or mixed prac-
tices (5 studies, RR 0.66, 95% CI 0.31 to 1.38) (test for
subgroup differences: p=0.55).
Mortality
Thirteen trials reported 422 deaths from any cause in a
total of 6537 participants.39 42 43 46 47 49–52 54 56 57 60
There was no statistically signiﬁcant difference in all-
cause mortality between self-monitoring and standard
clinical monitoring (RR 0.83, 95% CI 0.63 to 1.10,
p=0.20) (ﬁgure 5). Trials of self-management found a
reduction in mortality which was close to statistical sig-
niﬁcance (RR 0.68, 95% CI 0.46 to 1.01, p=0.06), and
similar in size and direction to the observed reduction
in thromboembolic events. Self-testing had no effect on
mortality (RR 0.97 95% CI 0.78 to 1.19, p=0.74).
There was an apparent signiﬁcant reduction in mortal-
ity in trials which restricted entry to patients with AHV
(4 trials, RR 0.54, 95% CI 0.32 to 0.92, p=0.02) and no
reduction in mortality in trials with mixed clinical indi-
cations for anticoagulant therapy (RR 0.95, 95% CI 0.78
to 1.16, p=0.61). As none of the trials reporting mortality
speciﬁcally excluded patients with AHVs, we could not
conclude from the pooled data whether this difference
by indication was clinically meaningful.
Deaths directly associated with anticoagulation therapy
were reported in ﬁve trials.42 43 47 50 51 In total, six
deaths related to anticoagulation therapy occurred
among participants receiving usual monitoring
care42 50 51 (1 valve thrombosis, 2 myocardial infarctions,
1 retroperitoneal haemorrhage, 1 cerebral haemor-
rhage, and 1 gastrointestinal bleeding) and seven deaths
occurred among participants who self-managed their
coagulation status (1 valve thrombosis, 1 pulmonary
embolism, 1 massive ischaemic stroke, 2 myocardial
infarctions, 1 cerebral haemorrhage, and 1 gastrointes-
tinal bleeding).43 47
Figure 3 Forest plot of comparison: major bleeding events.
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Anticoagulation control: target range
Table 4 summarises the results of anticoagulation
control reported in the included studies. There was a
great variation between trials in the measures used to
assess INR time and the values in TTR. In general, INR
time and INR values in TTR were reported to be higher
Figure 4 Forest plot of comparison: thromboembolic events.
Figure 5 Forest plot of comparison: mortality.
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Table 4 INR time and value in therapeutic range
Study ID
INR time in therapeutic range, mean % (SD) INR value in target range, % of INR values (95% CI)
PSM/PST Control p Value PSM/PST Control p Value
Azarnoush et al 201156 61.5 (19.3) 55.5 (19.9) 0.0343 NR NR NR
Bauman et al 201063 PSM: 83 (NR)
PST: 83.9 (NR)
– NR NR NR NR
Christensen et al 200639 78.7 (69.2–81.0)* 68.9 (59.3–78.2)* 0.14 NR NR NR
Christensen 201157 80.2 (2.3) 72.7 (2.6) <0.001 80.8 (79.3–82.1) 67.2 (64.1–70.2) <0.001
Cromheecke et al 200040 NR NR NS 55 (NR) 49 (NR) 0.06
Eitz et al 200841 NR NR 79 (NR) 65 (NR) <0.001
Fitzmaurice et al 200242 74 (16.2) 77 (23.5) NS 66 (61–71) 72 (65–80) NS
Fitzmaurice et al 200543 70 (20.1) 68 (23.0) 0.18 70 (64.8–74.8)† 72 (66.3 to 77.1)† NS
Gadisseur et al 200362 PSM: 68.6 (16.8)
PST: 66.9 (14.9)
67.9 (19.5) 0.33 66.3 (61–71.5)/
63.9 (59.8–68)‡
61.3 (55–62.4)/58.7‡ 0.14
Gardiner et al 200664 PSM: 69.9 (23.1)
PST: 71.8 (22.1)
– 0.46 NR NR NR
Horstkotte et al 199645 NR NR 43.2 (NR) 22.3 (NR) <0.001
Khan et al 200459 71.1 (14.5) 70.4 (24.5) NS NR NR NR
Kortke et al 200146 NR NR NR 79.2 (NR) 64.9 (NR) <0.001
Matchar et al 201060 66.2 (14.2) 62.4 (17.1) <0.001 NR NR NR
Menendez-Jandula et al 200547 64.3 (14.3) 64.9 (19.9) 0.2 58.6 (SD 14.3)† 55.6 (SD 19.6)† 0.02
Rasmussen et al 201248 52 (33–65)§ 55 (49–66) NR NR NR NR
Ryan et al 200961 74 (64.6–81)¶ 58.6 (45.6–73.1)¶ <0.001 NR NR NR
Sawicki 199949 NR NR NR 53 (NR)† 43.2 (NR)† 0.22
Sidhu and O’Kane 200150 76.5 (NR) 63.8 (NR) <0.0001 NR NR NR
Siebenhofer et al 200851 75.4 (9.4, 85.0)¶ 66.5 (47.1, 81.5)¶ <0.001 NR NR NR
Soliman Hamad et al 200952 NR NR NR 72.9 (SD 11)† 53.9 (SD 14)† 0.01
Sunderji et al 200453 71.8 (45.69) 63.2 (48.53) 0.14 NR NR NR
Verret et al 201254 80 (13.5) 75.5 (24.7) 0.79 NR NR NR
Völler et al 200555 178.8 (126)** 155.9 (118.4)** NS 67.8 (SD 17.6) 58.5 (SD 19.8) 0.0061
*Median % (95% CI).
†mean % of individual (95% CI).
‡% (95% CI).
§Median % (25–75 centile).
¶Median % (IQR).
**Mean cumulative days (SD).
INR, international normalised ratio; PSM, patient self-management; PST, patient self-testing; NR, not reported; NS, not significant.
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among self-monitoring participants compared with those
in standard care (table 4). Pooling of INR values in
TTR across trials proved unfeasible. Eighteen
trials38 39 42 43 47 48 50 51 53–57 59–64 provided data on INR
time in TTR and pooling of results was possible for 10
trials that provided suitable data.42 43 47 53 54 56 57 59 60 62
No statistically signiﬁcant differences were observed
between self-management and standard care with regard
to TTR (p=0.62) (table 3 and ﬁgure 6). Nevertheless, a
modest but signiﬁcantly higher proportion of TTR was
found for participants who self-tested compared with
those who received standard care (WMD 4.44, p=0.001)
(table 3 and ﬁgure 6).
The other intermediate outcomes were sparsely
reported in the included studies. Two trials reported
good patient compliance with self-monitoring (75% and
98%, respectively).58 59
Cost effectiveness
Applying the base case assumptions presented in table 1,
the results of the cost-effectiveness analyses indicate that
over a 10-year period, the introduction of self-
monitoring would reduce the proportion of people suf-
fering a thromboembolic event by 2.5%, while slightly
increasing the proportion suffering a major haemor-
rhagic event by 1.2% (table 5). While the predicted
monitoring costs are higher with self-monitoring, the
total health and social care costs are similar: £7324 for
standard care monitoring and £7326 for self-monitoring
(table 5). The estimated QALY gain associated with self-
monitoring was 0.028. Self-monitoring (50% self-testing,
50% self-management) appears to be cost-effective due
to its positive impact on the incidence of thrombo-
embolic events, even though, compared with mixed
primary/secondary care, it is likely to increase the INR
Figure 6 Forest plot of comparison: time in therapeutic range.
Table 5 Mean costs, outcomes and incremental cost-effectiveness over a 10-year time-horizon
Strategy
Mean
costs
Cumulative
monitoring/
device
costs
% with
first TE
event
% with
first major
bleed
Mean
QALYs
Incremental
cost
Incremental
QALYs ICER
Self-monitoring (50% self-management, 50% self-testing) versus standard care
Standard
monitoring
£7324 £1269 14.2 30.2 5.479 – – –
Self-monitoring £7326 £1944 11.7 31.4 5.507 £2 0.028 £71
Base case—100% self-management versus standard care
Standard
monitoring
£7324 £1269 14.2 30.2 5.479 – – –
Self-management
100%
£6394 £1717 9.2 32.7 5.535 −£930 0.056 Dominant
Base case—100% self-testing versus standard care
Standard
monitoring
£7324 £1269 14.2 30.2 5.479 – – –
Self-testing 100% £8258 £2171 14.2 30.1 5.479 £934 0 £2 811 298
TE, thromboembolic; QALYs, quality adjusted life years; ICER, incremental cost-effectiveness ratio.
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monitoring costs. Figure 7 shows that self-monitoring as
a whole has an approximately 80% chance of being con-
sidered cost-effective at a willingness to pay ratio of
£20 000 per QALY gained. However, the pooled relative
effect estimate for self-testing on thromboembolic events
(ﬁgure 4) is small and non-signiﬁcant (RR 0.99), while
the effect estimate for self-management is large (RR
0.51) and signiﬁcant. Thus, within the base case model,
self-management alone is highly cost-effective (ie, dom-
inant), while self-testing is not (table 5).
Further analysis of uncertainty
In an alternative speciﬁcation of the model, the overall
pooled effect estimates obtained from all self-testing and
self-management trials were applied to the self-testing
and self-management strategies. Under this scenario, self-
monitoring as a whole was found to be cost-saving over
standard care (see online supplementary appendix 5
table S3).
Two key parameters underpinning the cost-effectiveness
ﬁndings are the baseline risk of thromboembolic events,
and the relative effect of self-monitoring on these events.
The model ﬁndings were robust to individual changes in
these parameters through feasible ranges. However, when
a lower baseline risk of thromboembolic events (1.15%)
was combined with the upper 95% conﬁdence limit for
the RA associated self-management (RR 0.69), the incre-
mental cost-effectiveness ratio (ICER) for self-monitoring
as a whole rose above £30 000 per QALY. The same was
found when the lower baseline risk of thromboembolic
events was coupled with the upper conﬁdence limit of the
pooled RA for self-monitoring (RR 0.89). It should be
noted, however, that self-management alone remained
cost-saving under the former combined scenario. The cost-
effectiveness of self-monitoring improved further when
the modelled time horizon was extended to 20 and
30 years, dominating standard primary/secondary care
based monitoring. The incremental cost per QALY gained
for self-monitoring also remained below £20 000 when
higher training failure and discontinuation rates were
applied, and when higher self-monitoring testing frequen-
cies were applied (with no change in effects).
Alternative scenarios assessed the potential for self-
monitoring to be cost-saving if used to replace clinic-based
testing without increasing the frequency of testing (see
online supplementary appendix 5 table S4). Under these
scenarios it was assumed that there would be no effect on
the number of thromboembolic or bleeding events, and a
cost-minimisation approach was adopted. This showed that,
when holding all other base case parameters constant, self-
testing and self-management were more costly than stand-
ard primary care monitoring (ie, physician ofﬁces and
general practices), but less costly than standard secondary
care monitoring (ie, specialised anticoagulation clinics).
DISCUSSION
Our ﬁndings suggest that self-monitoring of anticoagula-
tion at home is at least as safe and effective as standard
clinic monitoring. Self-management of anticoagulation is
associated with reductions in thromboembolic events and
possibly, in all-cause mortality. INR time in TTR was
reported to be higher in self-monitoring participants com-
pared with standard clinical care. Self-monitoring, and in
particular self-management, of anticoagulation status
appeared cost-effective at a willingness to pay threshold of
£20 000 per QALY gained when pooled estimates of clin-
ical effectiveness were applied to the economic model.
The modelled reduction in thromboembolic events was
the key driver of cost-effectiveness.
The differences we observed between self-management
and self-testing are difﬁcult to explain. Paradoxically,
those who self-tested, rather than self-managed, spent
more time in TTR (and had more minor bleeding
events), but those who self-managed experienced less
thromboembolic events. It is possible that people who
self-managed their coagulation status take a more active
role in managing their therapy or that self-testing leads to
more rapid or frequent dose changes. It is also worth
noting that the meta-analyses results on self-testing were
dominated by the results of the largest trial published so
far, the Home International Normalised Ratio Study
(THINRS),60 which enrolled 2922 people and assessed
self-testing versus routine clinical care. This trial had a
specialised routine coagulation control and the longest
follow-up period (mean 3 years). The high quality of the
routine care in the THINRS may exceed current monitor-
ing care for anticoagulation control and could explain
the lack of signiﬁcant differences in major clinical
adverse events between self-testing and routine care.
When we excluded this trial from the statistical analyses,
the risk ratio for thromboembolic events fell from 0.99 to
0.55 among self-testing participants, although the CIs
widened (95% CI 0.13 to 2.31).
On the whole, our ﬁndings are broadly consistent with
those of previously published systematic reviews on
self-monitoring using point-of-care devices for the
Figure 7 Cost-effectiveness acceptability curves:
self-monitoring versus standard care.
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management of anticoagulation therapy, which found
that self-monitoring was associated with a signiﬁcant
reduction in the occurrence of thromboembolic events
and all-cause-mortality.14 16 20 27 29 66–69 Our economic
model, in accordance with previous economic evalua-
tions,29 34 indicates that self-monitoring is likely to be
cost-effective. The ﬁndings of our economic model are
also broadly in line with those of previous UK-based eco-
nomic assessments, in that self-monitoring (under base
assumptions) will increase the monitoring costs to the
NHS. However, our base case differs from that of previ-
ous UK evaluations in that the pooled relative effects for
self-management and self-testing, compared with stand-
ard care, were applied. We observed signiﬁcant future
cost savings and quality of life gains as a consequence of
a signiﬁcant reduction in the incidence of thrombo-
embolic events. This, in turn, translated into more
favourable estimates of cost-effectiveness. Further differ-
ences between the current analysis and the previous
UK-based model include the application of higher stand-
ard secondary care monitoring costs, lower self-
monitoring device costs (in line with current prices),
and higher acute treatment costs for stroke and major
bleeding events. Our analyses suggest that the cost-
effectiveness of self-monitoring is robust to variations in
these parameters when pooled clinical effect estimates
are applied to the model.
In more general terms, home monitoring, and espe-
cially self-management, of anticoagulation therapy may
have a substantial impact on the quality of life of
patients and their families. It may reduce the anxiety
associated with the fear of deviating from the thera-
peutic target range and boost conﬁdence in the therapy,
increase independence and psychological well-being,
and allow for the more efﬁcient organisation of time
(eg, travelling, social interactions).
Limitations
This study has been conducted as per recommended
methodological standards and is the most up-to-date evi-
dence synthesis on this topic with the largest number of
included RCTs.20 66 68
There are, however, potential limitations. The litera-
ture searches were performed in 2013 and were not sub-
sequently updated. While the meta-analysis results
demonstrated low statistical heterogeneity, which made it
statistically reasonable to combine the studies, uncertain-
ties remain that clinical heterogeneity could have con-
tributed to over or underestimate the effects. The
included trials varied in terms of clinical indications for
anticoagulation therapy, type of control care, reporting
structure for the time and/or values in TTR, the mode
and structure of the preintervention training and educa-
tion programme, length of follow-up, and methodo-
logical study quality. The majority of the trials included
participants with mixed clinical indications for anticoa-
gulation therapy, which made it challenging to extrapo-
late the results to speciﬁc clinical populations. In
particular, only limited data were available for people
with AF and consequently, no ﬁrm conclusions could be
drawn in relation to this patient population is.
Nevertheless, it likely that self-monitoring may produce
similar clinical beneﬁts in people with AF to those
achieved in people with artiﬁcial heart valves. A great
variation between trials was found in the way both INR
time and INR values in TTR were measured, which ham-
pered further analyses.
Assuming there is no interaction between the TTR
and the relative treatment effect for self-management on
thromboembolic events, our modelling suggests that it
will remain cost-effective even where TTR is high and
the thromboembolic event rate is low. However, it is pos-
sible that the quality of standard care may modify the
effectiveness of self-monitoring, and in turn, inﬂuence
its cost-effectiveness. Where patients are already achiev-
ing a very high level of INR control, this may limit the
potential for self-monitoring to improve TRR and in
turn, reduce thromboembolic event. With regard to the
economic model, there is still a certain degree of uncer-
tainty surrounding the pooled clinical effectiveness esti-
mates, especially for self-testing. It is worth noting that
the perspective of the cost-effectiveness analysis was that
of the National Health Service (NHS) and personal
social services. Therefore, our modelling fails to capture
any wider beneﬁts or cost-savings to patients and their
families, such as a reduction in time spent travelling to
and waiting in clinics.
Generally, adherence to self-monitoring was reported
to be high in the included trials (more than 90%).
However, all included trials enrolled highly selected
samples of people requiring anticoagulation therapy,
and so it was uncertain whether there was strong exter-
nal validity. To be enrolled in the trials, participants
needed to demonstrate adequate cognitive and physical
abilities, as well as dexterity and conﬁdence in using the
point-of-care device. In some of the included
trials42 43 47 62 a considerable proportion of eligible par-
ticipants (up to 50%) ultimately were not considered
suitable for inclusion. Despite the enrolment restric-
tions, results are valid for the patients groups included,
which actually represent the population who would be
considered for self-monitoring in clinical practices. Six
of the trials were conducted in the UK and we could not
ﬁnd any evidence that the UK trial patient cohorts were
fundamentally different from those of the rest of the
included studies.
Whilst new non-vitamin K antagonist oral anticoagulants
were beyond the scope of this assessment, these offer an
alternative option for many people with AF who are cur-
rently on warfarin. However, these are not suitable for all
people who need anticoagulation therapy. Furthermore,
due to the potential risk of bleeding, it is unlikely that
people receiving warfarin who have stable INR may switch
to the NOACs. Therefore, there are still many people who
receive warfarin rather than the NOACs for whom self-
monitoring is still of clinical relevance.
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CONCLUSIONS
Self-monitoring, and in particular self-management, is a
safe and cost-effective option for people requiring long-
term vitamin K antagonist therapy. Further research
assessing the longer-term outcomes of self-management
versus standard monitoring care as well as the compara-
tive effectiveness of various point-of-care coagulometers
would be useful. The technology related to these devices
is constantly changing and future research needs to
target larger cohorts of people with different clinical
indications requiring long-term anticoagulation therapy.
It is worth acknowledging that the modern point-of-care
coagulometers are likely to have advanced both in their
ease of use and cost, which, in theory, could modify the
possible candidates for these devices as well as the mag-
nitude of any economic evaluation.
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